Skip to content
Homepage
Author:
Prime Medicine, Inc.
Posted Date:
July 8, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine, Inc.
July 8, 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine, Inc.
June 22, 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine, Inc.
June 18, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc.
June 3, 2026
Prime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc.
May 28, 2026
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc.
May 7, 2026
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine, Inc.
April 16, 2026
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine, Inc.
March 3, 2026
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc.
February 25, 2026
